RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal Year Ended March 31, 2006
Business Overview: DRL is an emerging global pharmaceutical company headquartered in Hyderabad, India. Its principal operations include formulations, active pharmaceutical ingredients (APIs) and intermediates, generics, custom pharmaceutical services, critical care and biotechnology, and drug discovery. The company markets products globally with a focus on India, the United States, Europe, and Russia.

Key Financial Metrics (Fiscal Year 2006)

Note: U.S. dollar translations are based on the exchange rate of Rs. 44.48 per U.S.$1.00 as of March 31, 2006.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by 24.3% to Rs. 24,267.0 million from Rs. 19,519.4 million in fiscal 2005. This growth was driven by organic growth in formulations and API segments, as well as the consolidation of two major acquisitions: Industrias Quimicas Falcon de Mexico (Falcon) and beta Holding GmbH (betapharm).
• Profitability Turnaround: The company reported an operating income of Rs. 1,441.9 million in 2006, a significant improvement from an operating loss of Rs. 289.1 million in 2005. Net income surged to Rs. 1,628.9 million from Rs. 211.2 million in the prior year.
• Acquisition Impact:
  • betapharm: Acquired in March 2006 for approximately Rs. 26,063 million (Euro 482.6 million). It contributed Rs. 704.9 million in revenue for the period from March 3, 2006, to March 31, 2006.
  • Falcon: Acquired in December 2005 for approximately Rs. 2,773 million (U.S.$61 million). It contributed Rs. 804 million in revenue for the period from December 30, 2005, to March 31, 2006.
• Segment Performance:
  • Formulations: Revenue increased 26.9% to Rs. 9,925.9 million, driven by growth in India and Russia.
  • APIs: Revenue increased 18.6% to Rs. 8,238.0 million.
  • Generics: Revenue increased 13.4% to Rs. 4,055.8 million, largely due to the inclusion of betapharm. Excluding betapharm, organic generics revenue declined 6.3% due to pricing pressure in the U.S. market.
  • Custom Pharmaceutical Services: Revenue grew significantly to Rs. 1,326.8 million, driven by the Falcon acquisition.
• Debt Levels: Long-term debt increased substantially to Rs. 20,937.1 million from Rs. 25.1 million in 2005, primarily due to a Euro 400 million loan facility secured to fund the betapharm acquisition.

Guidance, Outlook, and Risks

• Outlook: Management expects continued growth driven by key brand performance in India and Russia, new product launches in the generics pipeline (including fexofenadine, simvastatin, and finasteride), and the full-year impact of the Falcon and betapharm acquisitions in fiscal 2007.
• Key Risks:
  • Regulatory and Patent Litigation: The company faces ongoing patent challenges, notably regarding the generic version of Allegra (fexofenadine), which was launched in April 2006 while litigation with Sanofi-Aventis was pending. There are also risks related to regulatory approvals in the U.S. and Europe.
  • Competition and Pricing: Intense competition in the generics market, particularly in the U.S., has led to price erosion. In Germany, new healthcare reforms (AVWG) effective May 2006 have led to price cuts and mandatory rebates, negatively impacting the first quarter of fiscal 2007 performance.
  • Integration Risks: Successful integration of betapharm and Falcon is critical; failure to integrate could divert management attention and harm financial results.
  • Foreign Exchange: A significant portion of revenues is in foreign currencies (USD, Euro) while costs are largely in Indian Rupees. Appreciation of the Rupee could adversely affect results.
  • Legal Proceedings: The company is involved in environmental litigation in India and a price control dispute regarding Norfloxacin with the Indian government, though management believes additional liability is remote.

Important Facts for Investor Verification

• Acquisition Accounting: Verify the final purchase price allocation for betapharm and Falcon, as the initial allocation was preliminary and subject to revision based on third-party valuations expected by December 31, 2006.
• Stock Dividend: A 1-for-1 stock dividend was approved in July 2006 and paid in August 2006. Historical per-share data in the filing has not been restated to reflect this split.
• Debt Covenants: Review the financial covenants associated with the Euro 400 million loan for betapharm, specifically the Consolidated Net Debt to Consolidated EBITDA ratio (not more than 4x, decreasing to 3x by March 31, 2008).
• Patent Litigation Status: Monitor the outcome of the pending litigation regarding fexofenadine (Allegra) and the authorized generic agreements with Merck for finasteride and simvastatin.
• German Market Exposure: Assess the impact of the German AVWG legislation on betapharm's pricing and profitability in the coming quarters.